MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517091156 A) filed by Ractigen Therapeutics, Jiangsu, China, on Sept. 23, for 'oligonucleotide targeting sod1.'
Inventor(s) include Li, Longcheng; and Kang, Moorim.
The application for the patent was published on Oct. 10, under issue no. 41/2025.
According to the abstract released by the Intellectual Property India: "Provided is a siRNA or an oligonucleotide agent for preventing or treating SOD1-associated neurodegenerative diseases or symptoms (such as amyotrophic lateral sclerosis, ALS). The oligonucleotide agent comprises a double-stranded targeting oligonucleotide (siRNA) and a non-targeting single-stranded oligonucleotide (ACO), in which the siRNA targets a mRNA region of the target gene SOD1."
The patent application was internationally filed on Feb. 23, 2024, under International application No.PCT/CN2024/078297.
Disclaimer: Curated by HT Syndication.
